A randomized, double blind (sponsor open), comparative, multi-center study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab co-administration in subjects with primary Sjögren’s syndrome. GlaxoSmithKline plc. granted: €114.000,- (2015, January 01 – 2017, December 31).